# Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia

Study · id `cardio:ct-nct03156842` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03156842](<https://clinicaltrials.gov/study/NCT03156842>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03156842

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 138 participants.

## Technical summary

Registry record NCT03156842. Randomized; triple masking; primary purpose treatment. Start 2017-05-29 (actual); primary completion 2018-12-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 138 participants (enrolled count; ClinicalTrials.gov record NCT03156842, source copy `cardio:ctgov-nct03156842-2019-06-10`, retrieved 2026-10-26)
- Started: 2017-05-29 (actual) (ClinicalTrials.gov record NCT03156842, source copy `cardio:ctgov-nct03156842-2019-06-10`, retrieved 2026-10-26)
- Primary completion: 2018-12-07 (actual) (ClinicalTrials.gov record NCT03156842, source copy `cardio:ctgov-nct03156842-2019-06-10`, retrieved 2026-10-26)
- Completion: 2018-12-07 (actual) (ClinicalTrials.gov record NCT03156842, source copy `cardio:ctgov-nct03156842-2019-06-10`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT03156842, source copy `cardio:ctgov-nct03156842-2019-06-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03156842-2019-06-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia
- Acronym: FIRST
- Condition: Essential Hypertension
- Condition: Dyslipidemia
- Intervention (Drug): Fimasartan/Amlodipine, Rosuvastatin
- Intervention (Drug): Fimasartan/Amlodipine
- Intervention (Drug): Fimasartan, Rosuvastatin
- Lead sponsor: Boryung Pharmaceutical Co., Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Boryung Pharmaceutical Co., Ltd (`cardio:org-boryung-pharmaceutical-co-ltd`)

## Provenance

Content hash: 2e7b1aa5b0cb3a5a0d2bfb9c38c55eb6b591cf69a9c3dd58f4526207fd4adb18
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
